Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 12,236 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Allergic Conjunctivitis
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psoriasis
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: KITE-585, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions: [Zr-89]Oxine-labeled leukocytes PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lymphocytic Leukemia, Chronic
Interventions: obinutuzumab, rituximab, chlorambucil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions: Family Centered pediatric palliative care for family caregivers of children with rare diseases.; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Months to 99 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Traumatic Hemorrhage, Hemorrhagic Shock
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Epilepsies, Partial
Interventions: SPN-804O; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Little Rock, Arkansas • Loxahatchee Groves, Florida • Tampa, Florida + 5 more

Conditions: Tobacco Use Disorder/Cigarette Smoking
Interventions: Multi-Theory Model (MTM)-Based Smoking Cessation Program; Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 29 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Trauma, Rib Fractures, Chest Wall Disorder, Respiratory Insufficiency, Pain, Chest, Rib Trauma, Rib Fracture Multiple, Respiratory Failure, Respiratory Distress Syndrome
Interventions: Percutaneous Cryoablation of Intercostal Nerves, Multi-modal pain regimen; Procedure · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Multiple Sclerosis
Interventions: Wahls Paleo Plus, Wahls Diet; Other
Lead sponsor: Terry L. Wahls; Other
Eligibility: 30 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer, Multiple Myeloma, Plasmacytoma
Interventions: sodium selenite, radiation therapy, laboratory biomarker analysis, pharmacological study, questionnaire administration; Drug · Radiation · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more

Conditions: Chronic Cluster Headache
Interventions: Eptinezumab; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Stamford, Connecticut • Ann Arbor, Michigan • Amherst, New York + 2 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: Irradiated haploidentical allogeneic lymphocytes, total-body irradiation; Biological · Radiation
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 13 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Hypotension, Orthostatic
Interventions: Midodrine hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 19 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Fort Wayne, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 8 more

Conditions: Peripheral Artery Disease
Interventions: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 39
States / cities: Yuma, Arizona • Fremont, California • Los Angeles, California + 34 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasm Female, Breast Cancer
Interventions: Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System, Placebo; Drug · Device
Lead sponsor: SBI ALApharma Canada, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Stamford, Connecticut • Clearwater, Florida • Miami, Florida + 4 more

Conditions: Ulcerative Colitis
Interventions: Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 81
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • La Jolla, California + 70 more

Conditions: Atrial Fibrillation
Interventions: RSD1235; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Huntsville, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Urinary Tract Infections
Interventions: SpeediCath, Conveen Uncoated; Device
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 12
States / cities: Downey, California • San Jose, California • Englewood, Colorado + 9 more

Conditions: Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions: Gentamicin, Lactobacillus Rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Search by objective public record fields.

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Multi-Center PAMPA Study

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Palliative Care Needs of Children With Rare Diseases and Their Families

The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

Smoking Cessation Intervention for Young Adults Using MTM: A Randomized Controlled Trial

Percutaneous Cryoablation of Intercostal Nerves for the Treatment of Rib Fractures

Wahls Paleo Diet and Progressive Multiple Sclerosis

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension

ILLUMENATE Pivotal Post-Approval Study (PAS)

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD